258 related articles for article (PubMed ID: 23714659)
1. [Effect of soluble PD-L1 released by lung cancer cells in regulating the function of T lymphocytes].
Shi MH; Xing YF; Zhang ZL; Huang JA; Chen YJ
Zhonghua Zhong Liu Za Zhi; 2013 Feb; 35(2):85-8. PubMed ID: 23714659
[TBL] [Abstract][Full Text] [Related]
2. [Effects of anti-PD-L1 monoclonal antibody and EGFR-TKI on the expression of PD-L1 and function of T lymphocytes in EGFR-mutated lung cancer cells].
She Y; Pan X; Xing YF; Zhou T; Zhang ZL; Shi MH; Chen YJ
Zhonghua Zhong Liu Za Zhi; 2016 Dec; 38(12):886-892. PubMed ID: 27998463
[No Abstract] [Full Text] [Related]
3. [Effect of cisplatin alone or combined with monoclonal anti-programmed death ligand-1 antibody on lung adenocarcinoma cell line SPCA-1 and T lymphocytes].
Pan X; Xing Y; Shi M; Zhou T; Qian B; Chen Y
Zhonghua Jie He He Hu Xi Za Zhi; 2014 Jun; 37(6):416-20. PubMed ID: 25200040
[TBL] [Abstract][Full Text] [Related]
4. Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.
Chen N; Fang W; Zhan J; Hong S; Tang Y; Kang S; Zhang Y; He X; Zhou T; Qin T; Huang Y; Yi X; Zhang L
J Thorac Oncol; 2015 Jun; 10(6):910-23. PubMed ID: 25658629
[TBL] [Abstract][Full Text] [Related]
5. Increased PD-1 on CD4(+)CD28(-) T cell and soluble PD-1 ligand-1 in patients with T2DM: association with atherosclerotic macrovascular diseases.
Shi B; Du X; Wang Q; Chen Y; Zhang X
Metabolism; 2013 Jun; 62(6):778-85. PubMed ID: 23398844
[TBL] [Abstract][Full Text] [Related]
6. [Effects of soluble programmed death ligand 1 on regulating the proliferation of T lymphocytes and its mechanism].
Zhao J; Pan X; Xing Y; Lu M; Chen Y; Shi M
Zhonghua Yi Xue Za Zhi; 2015 Feb; 95(6):449-52. PubMed ID: 25916783
[TBL] [Abstract][Full Text] [Related]
7. [Expression of PD-1/PD-L1 in peripheral blood mononuclear cells in lung cancer patients and its biological significance].
Xu P; Chen H; Chen YJ; Chen YB; Gu GH; Wu MY; Wu MJ; Wang XF; Zhang XG
Zhonghua Zhong Liu Za Zhi; 2013 Dec; 35(12):910-3. PubMed ID: 24506960
[TBL] [Abstract][Full Text] [Related]
8. Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis.
Black M; Barsoum IB; Truesdell P; Cotechini T; Macdonald-Goodfellow SK; Petroff M; Siemens DR; Koti M; Craig AW; Graham CH
Oncotarget; 2016 Mar; 7(9):10557-67. PubMed ID: 26859684
[TBL] [Abstract][Full Text] [Related]
9. Elevated Soluble PD-L1 in Pregnant Women's Serum Suppresses the Immune Reaction.
Okuyama M; Mezawa H; Kawai T; Urashima M
Front Immunol; 2019; 10():86. PubMed ID: 30833943
[No Abstract] [Full Text] [Related]
10. Upregulation of Programmed Death-1 and Its Ligand in Cardiac Injury Models: Interaction with GADD153.
Baban B; Liu JY; Qin X; Weintraub NL; Mozaffari MS
PLoS One; 2015; 10(4):e0124059. PubMed ID: 25902191
[TBL] [Abstract][Full Text] [Related]
11. Different roles of PD-L1 and FasL in immunomodulation mediated by human placenta-derived mesenchymal stem cells.
Gu YZ; Xue Q; Chen YJ; Yu GH; Qing MD; Shen Y; Wang MY; Shi Q; Zhang XG
Hum Immunol; 2013 Mar; 74(3):267-76. PubMed ID: 23261407
[TBL] [Abstract][Full Text] [Related]
12. PD-1/PD-L1 expression on CD(4+) T cells and myeloid DCs correlates with the immune pathogenesis of atrial fibrillation.
Liu L; Zheng Q; Lee J; Ma Z; Zhu Q; Wang Z
J Cell Mol Med; 2015 Jun; 19(6):1223-33. PubMed ID: 25810125
[TBL] [Abstract][Full Text] [Related]
13. Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody.
Stewart R; Morrow M; Hammond SA; Mulgrew K; Marcus D; Poon E; Watkins A; Mullins S; Chodorge M; Andrews J; Bannister D; Dick E; Crawford N; Parmentier J; Alimzhanov M; Babcook JS; Foltz IN; Buchanan A; Bedian V; Wilkinson RW; McCourt M
Cancer Immunol Res; 2015 Sep; 3(9):1052-62. PubMed ID: 25943534
[TBL] [Abstract][Full Text] [Related]
14. Association between PD-1/PD-L1 and T regulate cells in early recurrent miscarriage.
Li G; Lu C; Gao J; Wang X; Wu H; Lee C; Xing B; Zhang Q
Int J Clin Exp Pathol; 2015; 8(6):6512-8. PubMed ID: 26261529
[TBL] [Abstract][Full Text] [Related]
15. PD-1/PD-L1 signal pathway participates in HCV F protein-induced T cell dysfunction in chronic HCV infection.
Xiao W; Jiang LF; Deng XZ; Zhu DY; Pei JP; Xu ML; Li BJ; Wang CJ; Zhang JH; Zhang Q; Zhou ZX; Ding WL; Xu XD; Yue M
Immunol Res; 2016 Apr; 64(2):412-23. PubMed ID: 26286967
[TBL] [Abstract][Full Text] [Related]
16. Specific and high-affinity binding of tetramerized PD-L1 extracellular domain to PD-1-expressing cells: possible application to enhance T cell function.
Terawaki S; Tanaka Y; Nagakura T; Hayashi T; Shibayama S; Muroi K; Okazaki T; Mikami B; Garboczi DN; Honjo T; Minato N
Int Immunol; 2007 Jul; 19(7):881-90. PubMed ID: 17606978
[TBL] [Abstract][Full Text] [Related]
17. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells.
Barsoum IB; Smallwood CA; Siemens DR; Graham CH
Cancer Res; 2014 Feb; 74(3):665-74. PubMed ID: 24336068
[TBL] [Abstract][Full Text] [Related]
18. [Expression of PD-1 and PD-L1 in the peripheral blood of advanced non-small-cell lung cancer patients and its implications].
Xing YF; Pan X; Qian B; Shi MH
Zhonghua Yi Xue Za Zhi; 2019 Jan; 99(2):111-114. PubMed ID: 30669748
[No Abstract] [Full Text] [Related]
19. Inhibition of B-cell activation and antibody production by triggering inhibitory signals via the PD-1/PD-ligand pathway.
Buermann A; Römermann D; Baars W; Hundrieser J; Klempnauer J; Schwinzer R
Xenotransplantation; 2016 Sep; 23(5):347-56. PubMed ID: 27613101
[TBL] [Abstract][Full Text] [Related]
20. Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells.
Pen JJ; Keersmaecker BD; Heirman C; Corthals J; Liechtenstein T; Escors D; Thielemans K; Breckpot K
Gene Ther; 2014 Mar; 21(3):262-71. PubMed ID: 24401835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
